Abstract
A sensitive, selective and high throughput liquid chromatography tandem mass spectrometry (LC–ESI-MS/MS) method has been developed for the determination of teriflunomide, an active metabolite of leflunomide in human plasma. Plasma samples were prepared by liquid–liquid extraction of teriflunomide and valsartan as internal standard (IS) in ethyl acetate from 200
μL human plasma. The chromatographic separation was achieved on an Inertsil ODS-3 C18 (50
mm
×
4.6
mm, 3
μm) analytical column using isocratic mobile phase, consisting of 20
mM ammonium acetate–methanol (25:75, v/v), at a flow-rate of 0.8
mL/min. The precursor
→
product ion transition for teriflunomide (
m/
z 269.0
→
82.0) and IS (
m/
z 434.1
→
350.3) were monitored on a triple quadrupole mass spectrometer, operating in the multiple reaction monitoring (MRM) and negative ion mode. The method was validated over a wide dynamic concentration range of 10.1–4001
ng/mL. Matrix effect was assessed by post-column infusion experiment and the mean process efficiency were 91.7% and 88.2% for teriflunomide and IS respectively. The method was rugged and rapid with a total run time of 2.0
min and is applied to a bioequivalence study of 20
mg leflunomide (test and reference) tablet formulation in 12 healthy Indian male subjects under fasting condition.
